RRMM
FDA Approves Sarclisa Combination for Relapsed or Refractory Multiple Myeloma
The FDA approved isatuximab-irfc (Sarclisa, Sanofi Genzyme) in combination with carfilzomib and dexamethasone for ...
APRIL 6, 2021
FDA Approves Pepaxto for Triple-Refractory Multiple Myeloma
The FDA granted accelerated approval to melphalan flufenamide (Pepaxto, Oncopeptides AB) in combination with ...
MARCH 5, 2021
Subcutaneous Daratumumab-Based Regimen Effective for Advanced MM
The addition of subcutaneous daratumumab to the standard combination of pomalidomide and dexamethasone (Pd) ...
FEBRUARY 23, 2021
New Monoclonal Antibody Approved to Treat Relapsed/Refractory MM
The FDA approved isatuximab-irfc (Sarclisa, Sanofi) in combination with pomalidomide (Pomalyst, Celgene) and ...
MARCH 3, 2020
Long-Term Efficacy and Safety of ELd in RRMM Confirmed
Adding elotuzumab (Empliciti, Bristol-Myers Squibb) to lenalidomide (Revlimid, Celgene) and dexamethasone (ELd) ...
JUNE 26, 2017